Adrenomed presents new findings on its precision medicine treatment for septic shock with enibarcimab dur
Kort samengevat
Patient population benefitting most from enibarcimab treatment in septic shock can clearly be defined by two biomarkers, as shown by data presented todayIn the AdrenOSS-2 trial, the respective patient subgroup had a
Verder lezen bij de bron
Bekijk het volledige nieuwsbericht rechtstreeks bij Benzinga.
Lees het volledige bericht ↗